Non-analgesic effects of opioids: Mechanisms and potential clinical relevance of opioid-induced immunodepression

Current Pharmaceutical Design

Volumn 18, Issue 37, 2012, Pages 6034-6042

  Sacerdote, Paola ^a   Franchi, Silvia ^a   Panerai, Alberto E ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Cytokines; Immunity; Immunosuppression; Lymphocytes; Macrophages; Morphine; Opioid drugs

Indexed keywords

ANTINEOPLASTIC AGENT; BETA ENDORPHIN; BUPRENORPHINE; DOPAMINE 1 RECEPTOR; DYNORPHIN; FENTANYL; GAMMA INTERFERON; GLUCOCORTICOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 6; METENKEPHALIN; METHADONE; MORPHINE; MU OPIATE RECEPTOR; NALOXONE; OPIATE; PROTEIN KINASE C; TRAMADOL; TRANSCRIPTION FACTOR GATA 4; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ANALGESIA; ANTIBODY PRODUCTION; CANCER CHEMOTHERAPY; CELLULAR IMMUNITY; CONTINUOUS INFUSION; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG HALF LIFE; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; MACROPHAGE; NATURAL KILLER CELL; NEUROPATHIC PAIN; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OPIATE ADDICTION; PAIN; PHAGOCYTOSIS; POSTOPERATIVE PAIN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE; UPREGULATION;

ADAPTIVE IMMUNITY; ANIMALS; HUMANS; IMMUNE SYSTEM; IMMUNITY, INNATE; IMMUNOSUPPRESSIVE AGENTS; LIGANDS; NARCOTIC ANTAGONISTS; OPIOID PEPTIDES; OPIOID-RELATED DISORDERS; PAIN; RECEPTORS, OPIOID; SIGNAL TRANSDUCTION;

EID: 84873943621     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212803582496     Document Type: Review

References (102)

1. Sacerdote P. Opioid-induced immunosuppression. Curr Opin Support Palliat Care 2008; 2: 14-8.
2. Friedman H, Newton C, Klein TW. Microbial infections, immunomodulation, and drugs of abuse. Clin Microbiol Rev 2003; 16: 209-19.
3. Panerai AE, Sacerdote P. Beta-endorphin in the immune system: a role at last? Immunol Today 1997; 18: 317-9.
4. Risdahl JM, Khanna KV, Peterson PK, Molitor TW. Opiates and infection. J Neuroimmunol 1998; 83: 4-18.
5. Sharp BM. Multiple opioid receptors on immune cells modulate intracellular signaling. Brain Behav Immun 2006; 20: 9-14.
6. Bidlack JM, Khimich M, Parkhill AL, Sumagin S, Sun B, Tipton CM. Opioid receptors and signaling on cells from the immune system. J Neuroimmune Pharmacol 2006; 1: 260-9.
7. Roy S, Barke RA, Loh HH. MU-opioid receptor-knockout mice: role of mu-opioid receptor in morphine mediated immune functions. Brain Res Mol Brain Res 1998; 61: 190-4.
8. Gaveriaux-Ruff C, Matthes HW, Peluso J, Kieffer BL. Abolition of morphine-immunosuppression in mice lacking the mu-opioid receptor gene. Proc Natl Acad Sci USA 1998; 95: 6326-30.
9. Borner C, Stumm R, Hollt V, Kraus J. Comparative analysis of muopioid receptor expression in immune and neuronal cells. J Neuroimmunol 2007; 188: 56-63.
10. Kraus J, Borner C, Giannini E, Hollt V. The role of nuclear factor kappaB in tumor necrosis factor-regulated transcription of the human mu-opioid receptor gene. Mol Pharmacol 2003; 64: 876-84.
11. Kraus J, Borner C, Lendeckel U, Hollt V. Interferon-gamma downregulates transcription of the mu-opioid receptor gene in neuronal and immune cells. J Neuroimmunol 2006; 181: 13-8.
12. Kraus J, Borner C, Giannini E, et al. Regulation of mu-opioid receptor gene transcription by interleukin-4 and influence of an allelic variation within a STAT6 transcription factor binding site. J Biol Chem 2001; 276: 43901-8.
13. Borner C, Kraus J, Schroder H, Ammer H, Hollt V. Transcriptional regulation of the human mu-opioid receptor gene by interleukin-6. Mol Pharmacol 2004; 66: 1719-26.
14. Cabral GA. Drugs of abuse, immune modulation, and AIDS. J Neuroimmune Pharmacol 2006; 1: 280-95.
15. McCarthy L, Wetzel M, Sliker JK, Eisenstein TK, Rogers TJ. Opioids, opioid receptors, and the immune response. Drug Alcohol Depend 2001; 62: 111-23.
16. Wang J, Charboneau R, Balasubramanian S, Barke RA, Loh HH, Roy S. The immunosuppressive effects of chronic morphine treatment are partially dependent on corticosterone and mediated by the mu-opioid receptor. J Leukoc Biol 2002; 71: 782-90.
17. Fecho K, Maslonek KA, Dykstra LA, Lysle DT. Evidence for sympathetic and adrenal involvement in the immunomodulatory effects of acute morphine treatment in rats. J Pharmacol Exp Ther 1996; 277: 633-45.
18. Elenkov IJ, Wilder RL, Chrousos GP, Vizi ES. The sympathetic nerve--an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev 2000; 52: 595-638.
19. Weber RJ, Pert A. The periaqueductal gray-matter mediates opiate induced immunosuppression. Science 1989; 245: 188-90.
20. Hernandez M, Flores LR, Bayer BM. Immunosuppression by morphine Is mediated by central pathways. J Pharmacol Exp Ther 1993; 267: 336-1341
21. Saurer TB, Carrigan KA, Ijames SG, Lysle DT. Suppression of natural killer cell activity by morphine is mediated by the nucleus accumbens shell. J Neuroimmunol 2006; 173: 3-11.
22. Sacerdote P, Limiroli E, Gaspani L. Experimental evidence for immunomodulatory effects of opioids. Adv Exp Med Biol 2003; 521: 106-16.
23. Bajpai K, Singh VK, Agarwal SS, et al. Immunomodulatory activity of met-enkephalin and its two potent analogs. Int J Immunopharmacol 1995; 17: 207-12.
24. Gilman SC, Schwartz JM, Milner RJ, Bloom FE, Feldman JD. beta-Endorphin enhances lymphocyte proliferative responses. Proc Natl Acad Sci USA 1982; 79: 4226-30.
25. Dubinin KV, Zakharova LA, Khegai LA, Zaitsev SV. Immunomodulating effect of met-enkephalin on different stages of lymphocyte proliferation induced with concanavalin A in vitro. Immunopharmacol Immunotoxicol 1994; 16: 463-72.
26. Foris G, Medgyesi GA, Hauck M. Bidirectional effect of metenkephalin on macrophage effector functions. Mol Cell Biochem 1986; 69: 127-37.
27. Szabo I, Rojavin M, Bussiere JL, Eisenstein TK, Adler MW, Rogers TJ. Suppression of peritoneal macrophage phagocytosis of Candida albicans by opioids. J Pharmacol Exp Ther 1993; 267: 703-6.
28. Shahabi NA, Sharp BM. Delta opioid agonists inhibit proliferation of highlypurified murine CD4+ and CD8+ T-cells. Adv Exp Med Biol 1995; 373: 29-36.
29. Sharp BM, Keane WF, Suh HJ, Gekker G, Tsukayama D, Peterson PK. Opioid peptides rapidly stimulate superoxide production by human polymorphonuclear leukocytes and macrophages. Endocrinology 1985; 117: 793-5.
30. Heijnen CJ, Kavelaars A, Ballieux RE. Beta-endorphin: cytokine and neuropeptide. Immunol Rev 1991; 119: 41-63.
31. Manfredi B, Sacerdote P, Bianchi M, Locatelli L, Veljic-Radulovic J, Panerai AE. Evidence for an opioid inhibitory effect on T cell proliferation. J Neuroimmunol 1993; 44: 43-8.
32. Panerai AE, Manfredi B, Granucci F, Sacerdote P. The betaendorphin inhibition of mitogen-induced splenocytes proliferation is mediated by central and peripheral paracrine/autocrine effects of the opioid. J Neuroimmunol 1995; 58: 71-6.
33. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996; 17: 138-46.
34. Sacerdote P, Manfredi B, Gaspani L, Panerai AE. The opioid antagonist naloxone induces a shift from type 2 to type 1 cytokine pattern in BALB/cJ mice. Blood 2000; 95: 2031-6.
35. Sacerdote P, Gaspani L, Panerai AE. The opioid antagonist naloxone induces a shift from type 2 to type 1 cytokine pattern in normal and skin-grafted mice. Ann N Y Acad Sci 2000; 917: 755-63.
36. Sacerdote P, di San Secondo VE, Sirchia G, Manfredi B, Panerai AE. Endogenous opioids modulate allograft rejection time in mice: possible relation with Th1/Th2 cytokines. Clin Exp Immunol 1998; 113: 465-9.
37. Panerai AE, Radulovic J, Monastra G, Manfredi B, Locatelli L, Sacerdote P. Beta-endorphin concentrations in brain areas and peritoneal macrophages in rats susceptible and resistant to experimental allergic encephalomyelitis: a possible relationship between tumor necrosis factor alpha and opioids in the disease. J Neuroimmunol 1994; 51: 169-76.
38. Jamali A, Mahdavi M, Shahabi S, et al. Naloxone, an opioid receptor antagonist, enhances induction of protective immunity against HSV-1 infection in BALB/c mice. Microb Pathog 2007; 43: 217-23.
39. Jazani NH, Sohrabpour M, Mazloomi E, Shahabi S. A novel adjuvant, a mixture of alum and the general opioid antagonist naloxone, elicits both humoral and cellular immune responses for heat-killed Salmonella typhimurium vaccine. FEMS Immunol Med Microbiol 2011; 61: 54-62.
40. Machelska H, Stein C. Leukocyte-derived opioid peptides and inhibition of pain. J Neuroimmune Pharmacol 2006; 1: 90-7.
41. Akil H, Watson SJ, Young E, Lewis ME, Katchuturian H, Walter JM. Endogenous opioids: biology and function. Ann Rev Neurosci 1984; 7: 223-55.
42. Zagon IS, Donahue RN, Bonneaub, RH, McLaughlin PJ. B lymphocyte proliferation is suppressed by the opioid growth factoropioid growth factor receptor axis: Implication for the treatment of autoimmune diseases. Immunobiology 2011; 216: 173-83.
43. Zagon IS, Verderame MF, McLaughlin PJ. The biology of the opioid growth factor receptor (OGFr). Brain Res Rev 2002; 38: 351-76.
44. Zagon IS, Rahn KA, Turel AP, McLaughlin PJ. Endogenous opioids regulate expression of experimental autoimmune encephalomyelitis: a new paradigm for the treatment of multiple sclerosis. Exp Biol Med 2009; 234: 1383-92.
45. Wang J, Barke RA, Ma J, Charboneau R, Roy S. Opiate abuse, innate immunity, and bacterial infectious diseases. Arch Immunol Ther Exp (Warsz) 2008; 56: 299-309.
46. Wang J, Barke RA, Charboneau R, Roy S. Morphine impairs host innate immune response and increases susceptibility to Streptococcus pneumoniae lung infection. J Immunol 2005; 174: 426-34.
47. Martucci C, Franchi S, Lattuada D, Panerai AE, Sacerdote P. Differential involvement of RelB in morphine-induced modulation of chemotaxis, NO, and cytokine production in murine macrophages and lymphocytes. J Leukoc Biol 2007; 81: 344-54.
48. Wang J, Barke RA, Charboneau R, Schwendener R, Roy S. Morphine induces defects in early response of alveolar macrophages to Streptococcus pneumoniae by modulating TLR9-NF-kappa B signaling. J Immunol 2008; 180: 3594-600.
49. Ma J, Wang J, Wan J, et al. Morphine disrupts interleukin-23 (IL-23)/IL-17-mediated pulmonary mucosal host defense against Streptococcus pneumoniae infection. Infect Immun 2010; 78: 830-7.
50. Singhal PC, Kapasi AA, Franki N, Reddy K. Morphine-induced macrophage apoptosis: the role of transforming growth factor-beta. Immunology 2000; 100: 57-62.
51. Grimm MC, Ben-Baruch A, Taub DD, Howard OM, Wang JM, Oppenheim JJ. Opiate inhibition of chemokine-induced chemotaxis. Ann N Y Acad Sci 1998; 840: 9-20.
52. Zhang N, Oppenheim JJ. Crosstalk between chemokines and neuronal receptors bridges immune and nervous systems. J Leukoc Biol 2005; 78: 1210-4.
53. Kapadia F, Vlahov D, Donahoe RM, Friedland G. The role of substance of abuse in HIV disease progression: reconciling differences from laboratory and epidemiologic investigations. Clin Infect Dis 2004; 41: 1027-34
54. Wang J, Barke RA, Charboneau R, Loh HH, Roy S. Morphine negatively regulates interferon-gamma promoter activity in activated murine T cells through two distinct cyclic AMP-dependent pathways. J Biol Chem 2003; 278: 37622-31.
55. Wang J, Barke RA, Roy S. Transcriptional and epigenetic regulation of interleukin-2 gene in activated T cells by morphine. J Biol Chem 2007; 282: 7164-71.
56. Borner C, Warnick B, Smida M, et al. Mechanisms of opioidmediated inhibition of human T cell receptor signaling. J Immunol 2009; 183: 882-9.
57. Roy S, Wang J, Charboneau R, Loh HH, Barke RA. Morphine induces CD4+ T cell IL-4 expression through an adenylyl cyclase mechanism independent of the protein kinase A pathway. J Immunol 2005; 175: 6361-7.
58. Rahim RT, Meissler JJ Jr., Cowan A, et al. Administration of mu-, kappa-or delta2-receptor agonists via osmotic minipumps suppresses murine splenic antibody responses. Int Immunopharmacol 2001; 1: 2001-9.
59. Page GG. Immunologic effects of opioids in the presence or absence of pain. J Pain Symptom Manage 2005; 29: S25-31.
60. Franchi S, Panerai AE, Sacerdote P. Buprenorphine ameliorates the effect of surgery on hypothalamus-pituitary-adrenal axis, natural killer cell activity and metastatic colonization in rats in comparison with morphine or fentanyl treatment. Brain Behav Immun 2007; 21: 767-74.
61. Alexander M, Daniel T, Chaudry IH, Schwacha MG. Opiate analgesics contribute to the development of post-injury immunosuppression. J Surg Res 2005; 129: 161-8.
62. Sacerdote P, Bianchi M, Manfredi B, Panerai AE. Effects of tramadol on immune responses and nociceptive thresholds in mice. Pain 1997; 72: 325-30.
63. Gaspani L, Bianchi M, Limiroli E, Panerai AE, Sacerdote P. The analgesic drug tramadol prevents the effect of surgery on natural killer cell activity and metastatic colonization in rats. J Neuroimmunol 2002; 129: 18-24.
64. Beilin B, Shavit Y, Trabekin E, et al. The effects of postoperative pain management on immune response to surgery. Anesth Analg 2003; 97: 822-7.
65. Tsai YC, Won SJ, Lin MT. Effects of morphine on immune response in rats with sciatic constriction injury. Pain 2000; 88: 155-60.
66. Hutchinson MR, Shavit Y, Grace PM, Rice KC, Maier SF, Watkins LR. Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia. Pharmacol Rev 2011; 63: 772-810
67. Tsai YC, Won SJ. Effects of tramadol on T lymphocyte proliferation and natural killer cell activity in rats with sciatic constriction injury. Pain 2001; 92: 63-9.
68. Colacchio TA, Yeager MP, Hildebrandt LW. Perioperative immunomodulation in cancer surgery. Am J Surg 1994; 167: 174-9.
69. Hansbrough JF, Bender EM, Zapata-Sirvent R, Anderson J. Altered helper and suppressor lymphocyte populations in surgical patients. A measure of postoperative immunosuppression. Am J Surg 1984; 148: 303-7.
70. Ben-Eliyahu S, Page GG, Yirmiya R, Shakhar G. Evidence that stress and surgical interventions promote tumor development by suppressing natural killer cell activity. Int J Cancer 1999; 80: 880-8.
71. Martucci C, Panerai AE, Sacerdote P. Chronic fentanyl or buprenorphine infusion in the mouse: similar analgesic profile but different effects on immune responses. Pain 2004; 110: 385-92.
72. Shavit Y, Ben-Eliyahu S, Zeidel A, Beilin B. Effects of fentanyl on natural killer cell activity and on resistance to tumor metastasis in rats. Dose and timing study. Neuroimmunomodulation 2004; 11: 255-60.
73. Beilin B, Bessler H, Mayburd E, et al. Effects of preemptive analgesia on pain and cytokine production in the postoperative period. Anesthesiology 2003; 98(1): 151-5.
74. Gomez-Flores R, Weber RJ. Differential effects of buprenorphine and morphine on immune and neuroendocrine functions following acute administration in the rat mesencephalon periaqueductal gray. Immunopharmacology 2000; 48: 145-56.
75. D'Elia M, Patenaude J, Hamelin C, Garrel DR, Bernier J. No detrimental effect from chronic exposure to buprenorphine on corticosteroid-binding globulin and corticosensitive immune parameters. Clin Immunol 2003; 109: 179-87.
76. Tubaro E, Avico U, Santiangeli C, et al. Morphine and methadone impact on human phagocytic physiology. Int J Immunopharmacol 1985; 7: 865-74.
77. Pacifici R, Patrini G, Venier I, Parolaro D, Zuccaro P, Gori E. Effect of morphine and methadone acute treatment on immunological activity in mice: pharmacokinetic and pharmacodynamic correlates. J Pharmacol Exp Ther 1994; 269: 1112-6.
78. Yeager MP, Colacchio TA, Yu CT, et al. Morphine inhibits spontaneous and cytokine-enhanced natural killer cell cytotoxicity in volunteers. Anesthesiology 1995; 83: 500-8.
79. Yokota T, Uehara K, Nomoto Y. Addition of noradrenaline to intrathecal morphine augments the postoperative suppression of natural killer cell activity. J Anesth 2004; 18: 190-5.
80. Sacerdote P, Bianchi M, Gaspani L, et al. The effects of tramadol and morphine on immune responses and pain after surgery in cancer patients. Anesth Analg 2000; 90: 1411-4.
81. Wang ZY, Wang CQ, Yang JJ, et al. Which has the least immunity depression during postoperative analgesia--morphine, tramadol, or tramadol with lornoxicam? Clin Chim Acta 2006; 369: 40-5.
82. Beilin B, Grinevich G, Yardeni IZ, Bessler H. Tramadol does not impair the phagocytic capacity of human peripheral blood cells. Can J Anaesth 2005; 52: 1035-9.
83. Hashiguchi S, Morisaki H, Kotake Y, Takeda J. Effects of morphine and its metabolites on immune function in advanced cancer patients. J Clin Anesth 2005; 17: 575-80.
84. Jacobs R, Karst M, Scheinichen D, et al. Effects of fentanyl on cellular immune functions in man. Int J Immunopharmacol 1999; 21: 445-54.
85. Beilin B, Shavit Y, Hart J, et al. Effects of anesthesia based on large versus small doses of fentanyl on natural killer cell cytotoxicity in the perioperative period. Anesth Analg 1996; 82: 492-7.
86. Yardeni IZ, Beilin B, Mayburd E, Alcalay Y, Bessler H. Relationship between fentanyl dosage and immune function in the postoperative period. J Opioid Manag 2008; 4: 27-33.
87. Kaushik KS, Kapila K, Praharaj AK. Shooting up: the interface of microbial infections and drug abuse. J Med Microbiol 2011; 60: 408-22.
88. Donahoe RM, Vlahov D. Opiates as potential cofactors in progression of HIV-1 infections to AIDS. J Neuroimmunol 1998; 83: 77-87.
89. Sacerdote P, Franchi S, Gerra G, Leccese V, Panerai AE, Somaini L. Buprenorphine and methadone maintenance treatment of heroin addicts preserves immune function. Brain Behav Immun 2008; 22: 606-13.
90. Madden JJ, Falek A, Shafer DA, Glick JH. Effects of opiates and demographic factors on DNA repair synthesis in human leukocytes. Proc Natl Acad Sci USA 1979; 76: 5769-73.
91. Neri S, Bruno CM, Pulvirenti D, et al. Randomized clinical trial to compare the effects of methadone and buprenorphine on the immune system in drug abusers. Psychopharmacology (Berl) 2005; 179: 700-4.
92. Castle SC, Uyemura K, Fulop T, Makinodan T. Host resistance and immune responses in advanced age. Clin Geriatr Med 2007; 23: 463-79.
93. Vallejo R, de Leon-Casasola O, Benyamin R. Opioid therapy and immunosuppression: a review. Am J Ther 2004; 11: 354-65.
94. Martin JL, Charboneau R, Barke RA, Roy S. Chronic morphine treatment inhibits LPS-induced angiogenesis: implications in wound healing. Cell Immunol 2010; 265: 139-45.
95. Martin JL, Koodie L, Krishnan AG, Charboneau R, Barke RA, Roy S. Chronic morphine administration delays wound healing by inhibiting immune cell recruitment to the wound site. Am J Pathol 2010; 176: 786-99.
96. Yeager MP, Rosenkranz KM. Cancer recurrence after surgery: a role for regional anesthesia? Reg Anesth Pain Med 2010; 35: 483-4.
97. Reece AS. Clinical implications of addiction related immunosuppression. J Infect 2008; 56: 437-45.
98. Rittner HL, Roewer N, Brack A. The clinical (ir) relevance of opioid induced immune suppression. Curr Opin Anaesthesiol 2010; 23: 588-92
99. Brack A, Rittner HL, Stein C. Immunosuppressive effects of opioids-Clinical relevance Neuroimmune Pharmacol 2011; 6: 490-502
100. Murphy GS, Szokol JW, Marymont JH, Avram MJ, Vender JS. The effects of morphine and fentanyl on the inflammatory response to cardiopulmonary bypass in patients undergoing elective coronary artery bypass graft surgery. Anesth Analg 2007; 104: 1334-42, table of contents.
101. von Dossow V, Luetz A, Haas A, et al. Effects of remifentanil and fentanyl on the cell-mediated immune response in patients undergoing elective coronary artery bypass graft surgery. J Int Med Res 2008; 36: 1235-47.
102. Sacerdote P, Gaspani L, Rossoni G, Panerai AE, Bianchi M. Effect of the opioid remifentanil on cellular immune response in the rat. Int Immunopharmacol 2001; 1: 713-9.